Skip to content

Study · Not a test of the peptide alone · 2025

4 results

Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.

Simonian A, Sousa E, Samakar K, Vidmar AP

Obesity pillars1 Jul 2025Cited by 1 (Europe PMC)

PMID40698016 (opens in a new tab)PMCIDPMC12282260 (opens in a new tab)DOI10.1016/j.obpill.2025.100192 (opens in a new tab)PepBankPUB-40698016
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a child with optic nerve hypoplasia and severe obesity, triple-agent therapy including semaglutide gave a 30% BMI reduction over 24 months.

    In plain wordsIn one child with severe obesity, a three-drug regimen that included semaglutide was followed by a lower BMI.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction over 24 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    resulting in BMI reduction of 30 % over 24 months with triple-agent therapy
    1 context sentence
    Summary · context
    A Hispanic female was diagnosed at 45 days of life with ONH and central arginine vasopressin deficiency, central hypothyroidism, secondary adrenal insufficiency, and growth hormone deficiency.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a child with optic nerve hypoplasia and severe obesity, obstructive sleep apnea resolved with triple-agent therapy including semaglutide.

    In plain wordsIn one child, sleep apnea resolved while on a three-drug regimen that included semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseObstructive sleep apnea resolution
    Study

    n = 1

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    resulting in BMI reduction of 30 % over 24 months with triple-agent therapy, and associated resolution of OSA, elevated liver enzymes, and hypertriglyceridemia.
    1 context sentence
    Summary · context
    A Hispanic female was diagnosed at 45 days of life with ONH and central arginine vasopressin deficiency, central hypothyroidism, secondary adrenal insufficiency, and growth hormone deficiency.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a child with optic nerve hypoplasia and severe obesity, elevated liver enzymes resolved with triple-agent therapy including semaglutide.

    In plain wordsIn one child, raised liver enzymes returned to normal while on a three-drug regimen that included semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseElevated liver enzymes resolution
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    resulting in BMI reduction of 30 % over 24 months with triple-agent therapy, and associated resolution of OSA, elevated liver enzymes, and hypertriglyceridemia.
    1 context sentence
    Summary · context
    A Hispanic female was diagnosed at 45 days of life with ONH and central arginine vasopressin deficiency, central hypothyroidism, secondary adrenal insufficiency, and growth hormone deficiency.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a child with optic nerve hypoplasia and severe obesity, hypertriglyceridemia resolved with triple-agent therapy including semaglutide.

    In plain wordsIn one child, high blood triglycerides resolved while on a three-drug regimen that included semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHypertriglyceridemia resolution
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    resulting in BMI reduction of 30 % over 24 months with triple-agent therapy, and associated resolution of OSA, elevated liver enzymes, and hypertriglyceridemia.
    1 context sentence
    Summary · context
    A Hispanic female was diagnosed at 45 days of life with ONH and central arginine vasopressin deficiency, central hypothyroidism, secondary adrenal insufficiency, and growth hormone deficiency.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.